Navigation Links
Amgen's Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
Date:7/30/2013

to non-GAAP financial measures.  These adjustments and other items are presented on the attached reconciliations.Product Sales Performance

  • Total product sales increased 9 percent year-over-year.
  • Combined Neulasta and NEUPOGEN (filgrastim) sales increased 7 percent year-over-year.
  • Global Neulasta sales increased 10 percent driven by price increases, increases in wholesaler inventory and the Medicaid rebate adjustment, partially offset by unit declines.
  • Global NEUPOGEN sales declined 2 percent driven by lower units, partially offset by price increases and the Medicaid rebate adjustment. 
  • ENBREL sales increased 9 percent mainly driven by price increases.
  • Aranesp® (darbepoetin alfa) sales decreased 2 percent year-over-year.  Sequentially, sales were flat excluding the Medicaid rebate adjustment.
  • EPOGEN®(epoetin alfa) sales decreased 4 percent year-over-year.  Sequentially, sales increased 15 percent driven by an increase in units due to the peginesatide recall and the Medicaid rebate adjustment.
  • Sensipar®/Mimpara® (cinacalcet) sales increased 12 percent year-over-year driven by increases in unit demand.
  • Combined sales of Vectibix® (panitumumab) and Nplate® (romiplostim) increased 13 percent, mainly due to unit growth. 
  • XGEVA sales increased 39 percent year-over-year and 12 percent on a sequential basis, reflecting increased segment share.
  • Prolia sales increased 57 percent year-over-year and increased 32 percent on a sequential basis due to increased segment share, partially driven by seasonality.
  • Product Sales Detail by Product and Geographic Region 

    $Millions, except percentagesQ2 '13Q2 '12YOY ΔUSROWTOTALTOTALTOTALNeulasta®/ NEUPOGEN® $1,164

    $280


    '/>"/>

    SOURCE Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Covance Reports Second Quarter Net Revenue of $592 Million, Pro Forma EPS of $0.78 and Record Adjusted Net Orders of $776 Million
    2. Oncology remains most restrictive specialty for second year
    3. China Biologic Products to Report Second Quarter 2013 Financial Results
    4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
    5. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
    6. Webcast Alert: Isis Pharmaceuticals Second Quarter 2013 Financial Results Conference Call
    7. VirtualScopics Schedules Second Quarter 2013 Earnings Announcement
    8. Luminex Corporation Reports Second Quarter 2013 Results
    9. Endo to Announce Second Quarter 2013 Financial Results on August 6, 2013
    10. Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
    11. PDI, Inc. to Hold Second Quarter 2013 Financial Results Conference Call on Monday, August 5, 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2015)... Pa. , May 4, 2015 DePuy ... Dura Repair, the first commercially available biosynthesized dural ... Synthes CMF is a part of the DePuy Synthes ... is a tissue membrane that covers and protects the ... be cut to allow surgeons to access the brain. ...
    (Date:5/4/2015)... ANGELES , May 4, 2015 Former ... FOX News online last week where he discussed Theradome™, ... to be FDA-cleared. The FOX segment shows firsthand how, ... and affordable hair loss solution that will not require ... stimulates the mitochondria at the base of the hair ...
    (Date:5/4/2015)... TORONTO , May 4, 2015 /PRNewswire/ ... announced that it intends to dividend to its stockholders ... of a definitive licensing agreement to license its RapidMist™ ... ) (OTCQB:SMFI). As announced on April 23, ... in respect of the licensing of its RapidMist™ buccal ...
    Breaking Medicine Technology:DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 3FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5
    ... Aug. 21 Genetic testing can be,used to ... anticoagulant, according to research published in the,September 1, ... American Society of,Hematology. This result represents one of ... to guide personal medical care., Because individuals ...
    ... Randomized, Double-Blind Study Targets Biomarker-Defined Population, ... (Nasdaq: GNTA ) announced that the ... confirmatory Phase 3 trial of Genasense,(oblimersen sodium) ... as,AGENDA, is a randomized, double-blind, placebo-controlled study ...
    Cached Medicine Technology:Genetics Determine Optimal Drug Dose of Common Anticoagulant 2Genetics Determine Optimal Drug Dose of Common Anticoagulant 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5
    (Date:5/4/2015)... HHT is a rare but cruel ... it can have seemingly mild symptoms like frequent nosebleeds, ... Hereditary Hemorrhagic Telangiectasia (HHT) is a hereditary disorder resulting ... capillary connections between an artery and a vein. These ... but may also be present in the lungs, brain ...
    (Date:5/4/2015)... New York (PRWEB) May 04, 2015 ... as $2.4 billion to settle thousands of Actos lawsuits ... diabetes medication increases the risk that a patient will ... on April 28th, if 95% of those eligible for ... resolve nearly 9,000 bladder cancer cases currently pending in ...
    (Date:5/4/2015)... (PRWEB) May 04, 2015 “ LiveSchool ... monthly AppWatch, which takes a look at the latest ... and Windows. Joe Toohey, the host of AppWatch and ... viewers how this application allows teachers to reward students ... than some realize, especially in the classroom. And ...
    (Date:5/4/2015)... May 04, 2015 Baptist Medical ... Stroke Association’s Get With The Guidelines®-Stroke Gold Plus ... Honor Roll. The award recognizes the hospital’s commitment ... the most appropriate treatment according to nationally recognized, ... , To receive the Gold Plus Quality Achievement ...
    (Date:5/4/2015)... Ticket Down is a reputable source for authentic ... While the World Cup is the most known soccer ... the International Champions Cup is one of the biggest tournaments ... record for soccer in the United States set when Manchester ... University of Michigan. This year, the defending champion Manchester United ...
    Breaking Medicine News(10 mins):Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 3Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4
    ... , ... Strong Backbone for Victory: Cortical Concepts Wins ,Wharton Business Plan Competition Michelson Grand ... “People’s Choice” Award with Private Sales for Co-eds, , ... Philadelphia, PA (PRWEB) April 29, ...
    ... ... Science and Technology Policy, will bring together leaders in open innovation , ... Washington, DC (Vocus) -- This ... Grant Making”, a public-private strategy session jointly hosted by the White House Office on ...
    ... Athens, Ga. A team of researchers at the University ... the next five years from the National Institutes of Health ... may prevent drug abuse relapse. "Drug abuse is ... aspects of treating addiction is preventing the relapse caused by ...
    ... ... awarded a $4.2 million grant from the Ontario Ministry of Research and Innovation’s Biopharmaceutical ... expansion of its bio-manufacturing facility in Mississauga, Ontario, Canada. , ... Toronto, ON (Vocus) April 30, 2010 -- ...
    ... how the brain communicates with limbs, researcher says , THURSDAY, ... a phenomenon known as mirror movements has been identified by ... move one side of their body without moving the other. ... the same movement occurs unintentionally in the left hand. , ...
    ... ... has developed a unique caregiver testing program to measure the preparedness of home care ... ... 29, 2010 -- The National Private Duty Association (NPDA), a non-profit organization comprised of ...
    Cached Medicine News:Health News:Wharton Business Plan Competition Michelson Grand Prize Winners Announced 2Health News:Wharton Business Plan Competition Michelson Grand Prize Winners Announced 3Health News:Prize4Life Featured in Major Innovation/Prize National Conference 2Health News:Prize4Life Featured in Major Innovation/Prize National Conference 3Health News:UGA, Emory to study how exercise may prevent drug abuse relapse 2Health News:Therapure Awarded $4.2 Million BIP Grant from the Ontario Government 2Health News:Scientists Find Cause of Involuntary Mirror Movements 2Health News:Association Advocates Testing for Home Care Workers 2
    ... Wampole Laboratories offers a comprehensive line ... for serum and urine in convenient one-step ... offers 2 testing options. Clearview Easy HCG ... a convenient stick format. Clearview HCG ...
    ... line of pregnancy tests including rapid membrane ... one-step stick and cassette formats. The Clearview ... HCG is a 25 mIU urine test ... HCG II provides 25mIU sensitivity for urine ...
    For the quantitative determination of Glycohemoglobin (HbA1) in blood by,cation exchange resin. The test is to be used to monitor long-term glucose,control in diabetes mellitus....
    Rapid turn-around time, results in less than 4 hours...
    Medicine Products: